Mary Mulcahy is an Oncology physician. ClinicalTrials.gov lists 10 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
675 N Saint Clair St
Galter 21-100
Chicago, IL 606115975
Telephone
312-695-0990Registry record last updated 17 Jul 2009.
Clinical trials
- Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
Sponsor: Boston Scientific Corporation
- Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases
Sponsor: Northwestern University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Intera Oncology, IncProgram year20251 payment
- Ipsen Biopharmaceuticals, IncProgram year20251 payment
- Astellas Pharma US IncProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
57.7%CD38-directed Cytolytic Antibody20.2%Daratumumab100%Part B, office-administered≥64 patientsPlatinum-based Drug11.4%Oxaliplatin100%Part B, office-administered≥25 patients+ 7 more classes in this area
Metabolism & gastrointestinal
12.3%Other antiemetics9.4%Fosaprepitant100%Part B, office-administered≥40 patientsAnticholinergic1.5%Atropine sulfate100%Part B, office-administered≥25 patients+ 4 more classes in this area
Blood & clotting
10.1%Iron, parenteral preparations10%Ferric carboxymaltose100%Part B, office-administered≥15 patientsFactor Xa inhibitor0%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2006–2007 per NIH RePORTER. The latest:
- PHASE I/II STUDY OF OXALIPLATIN, 5-FLUOROURACIL AND DOCETAXEL FOR SOLID TUMORS
Northwestern University at Chicago
FY2007$5,484M01RR000048 - NU 0412: A PHASE I/II STUDY OF OXALIPLATIN, 5-FLUOROURACIL AND DOCETAXEL
Northwestern University at Chicago
FY2006$10,136M01RR000048
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”